FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

FERG.UK

18,990

+1.06%↑

Search

Syncona Ltd

Slēgts

102 3.55

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

98.3

Max

102

Galvenie mērījumi

By Trading Economics

Ienākumi

-68M

Pārdošana

44M

Peļņas marža

-153.576

Darbinieki

1,215

EBITDA

-49M

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 13. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

602M

Iepriekšējā atvēršanas cena

98.45

Iepriekšējā slēgšanas cena

102

Syncona Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 28. okt. 23:50 UTC

Karstas akcijas

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025. g. 28. okt. 23:25 UTC

Peļņas

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025. g. 28. okt. 23:18 UTC

Peļņas

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025. g. 28. okt. 22:20 UTC

Peļņas

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025. g. 28. okt. 22:13 UTC

Peļņas

Wal-Mart de Mexico Net Profit Falls in 3Q

2025. g. 28. okt. 21:38 UTC

Peļņas

Correction to Visa Sales Jump Article

2025. g. 28. okt. 21:17 UTC

Peļņas

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025. g. 28. okt. 21:07 UTC

Peļņas

Visa Sales Jump as Consumers Keep Spending -- Update

2025. g. 28. okt. 21:02 UTC

Peļņas

Mondelez Tempers Outlook as Costs Rise

2025. g. 28. okt. 23:51 UTC

Tirgus saruna

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025. g. 28. okt. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025. g. 28. okt. 23:02 UTC

Peļņas

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025. g. 28. okt. 23:01 UTC

Peļņas

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025. g. 28. okt. 22:46 UTC

Peļņas

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025. g. 28. okt. 22:45 UTC

Peļņas

SK Hynix 3Q Net KRW12.6T >000660.SE

2025. g. 28. okt. 22:44 UTC

Peļņas

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025. g. 28. okt. 22:43 UTC

Peļņas

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025. g. 28. okt. 22:42 UTC

Peļņas

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025. g. 28. okt. 22:40 UTC

Peļņas

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025. g. 28. okt. 22:40 UTC

Peļņas

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025. g. 28. okt. 22:20 UTC

Peļņas

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025. g. 28. okt. 22:02 UTC

Peļņas

Review & Preview: Earnings Extravaganza -- Barrons.com

2025. g. 28. okt. 21:42 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 28. okt. 21:42 UTC

Tirgus saruna
Peļņas

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025. g. 28. okt. 21:20 UTC

Peļņas

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025. g. 28. okt. 21:19 UTC

Peļņas

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025. g. 28. okt. 21:18 UTC

Peļņas

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Salīdzinājums

Cenas izmaiņa

Syncona Ltd Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

EBITDA

Pamatdarbības peļņa

$

Par Syncona Ltd

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
help-icon Live chat